FDA approves Gazyva as first treatment for primary membranous nephropathy

Photo: Anatomical model of a kidney. Robina Weermeijer / Unsplash

1. FDA approves Gazyva as first treatment for primary membranous nephropathy

Complete remission of proteinuria at two years: 36% versus 6% on tacrolimus.

The FDA on Nov. 13 approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria, the first drug approved specifically for the rare kidney disease [1]. In the Phase 3 MAJESTY trial of 142 adults, 36% of Gazyva patients reached complete remission of proteinuria at week 104, versus 6% on tacrolimus, which is sometimes used off-label for the condition [1]. The label carries a boxed warning for hepatitis B reactivation and progressive multifocal leukoencephalopathy; the approval carried Breakthrough Therapy, Orphan Drug and Priority Review designations [1].

2. FDA approves AstraZeneca's Klygefa, a weekly self-injected C5 inhibitor for myasthenia gravis

Patients can give the autoinjector dose themselves at home.

Alexion, AstraZeneca Rare Disease, announced Nov. 16 that the FDA approved Klygefa (gefurulimab) for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis [2]. In the 260-patient, 20-country Phase 3 PREVAIL trial, published in JAMA Neurology, Klygefa improved MG-ADL scores at week 26 by 1.6 points more than placebo, with improvement seen as early as week one [2]. Dosing is a weight-based loading dose on Day 1 and weekly subcutaneous maintenance doses from Day 8; the most common adverse events were injection site reactions (12%), back pain (8%) and vomiting (5%) [2].

3. CMS extends nationwide moratorium on new Medicare hospice enrollments six months, narrows scope

New practice locations for existing hospices are no longer blocked.

CMS extended its nationwide moratorium on initial Medicare hospice enrollments for another six months, effective Nov. 12, in a notice published in the Federal Register on Nov. 16 [3]. The extension now covers only newly enrolling hospices, including those enrolling through a non-exempt change in majority ownership, and no longer bars existing hospices from adding practice locations [3]. CMS cited ongoing HHS-OIG fraud concerns, recent California fraud convictions, and its 2023 enhanced oversight in Arizona, California, Nevada and Texas, where 122 of about 670 reviewed hospices were revoked, an 18% rate against the typical 1 to 3% [3].

4. CG Oncology's cretostimogene cut bladder cancer recurrence risk 68% in Phase 3 PIVOT-006

The company plans a second BLA in the second quarter of 2027.

CG Oncology said Nov. 16 that its intravesical oncolytic immunotherapy cretostimogene grenadenorepvec met the primary endpoint of recurrence-free survival in PIVOT-006, a randomized Phase 3 trial of adjuvant treatment versus surveillance after complete tumor resection in 367 patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer [4]. The hazard ratio was 0.32 (95% CI 0.23 to 0.45; p<0.0001) at a median follow-up of 17 months, with no Grade 3 or higher treatment-related adverse events [4]. These are topline results; full data are slated for the Society of Urologic Oncology meeting on Dec. 2 [4].

Digest references

  1. U.S. Food and Drug Administration, "FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy," Nov. 13, 2026. fda.gov

  2. AstraZeneca, "Klygefa approved in the US for generalised myasthenia gravis" (Form 6-K exhibit), Nov. 16, 2026. sec.gov

  3. Centers for Medicare & Medicaid Services, "Medicare Program; Extension of Nationwide Moratorium on Enrollment of New Hospices" (CMS-6102-N2), Federal Register public inspection, Nov. 16, 2026. federalregister.gov

  4. CG Oncology, "PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Results" (press release), Nov. 16, 2026. stocktitan.net

Katie Coffee

Professional photographer, Medical journalist, Business Development & Head of Marketing at Innovative Vascular Institute, from Louisiana, to Nashville. Medical PR

https://katiecoffeephoto.com
Previous
Previous

Sirtex acquires FDA-cleared Hourglass vascular plug for peripheral embolization

Next
Next

Synchron pauses trials of Stentrode brain implant over lead performance issue